NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings data on Wednesday, February, 6th. The biotechnology company reported $1.25 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.46 by $0.21. The biotechnology company had revenue of $69.89 million for the quarter, compared to the consensus estimate of $71.27 million. Enanta Pharmaceuticals had a return on equity of 22.78% and a net margin of 36.19%. The business's revenue for the quarter was up 83.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 earnings per share. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

6 equities research analysts have issued 1-year price targets for Enanta Pharmaceuticals' stock. Their predictions range from $80.00 to $133.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $102.60 in the next year. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Headlines about ENTA stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of 0.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.

Some companies that are related to Enanta Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), United Therapeutics (UTHR), Alkermes (ALKS), Array Biopharma (ARRY), GALAPAGOS NV/S (GLPG), FibroGen (FGEN) and GW Pharmaceuticals PLC- (GWPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include NVIDIA (NVDA), Zoetis (ZTS), Intercept Pharmaceuticals (ICPT), Dollar Tree (DLTR), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Celgene (CELG), Micron Technology (MU), Mastercard (MA) and ABIOMED (ABMD).

Enanta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.24%), First Manhattan Co. (3.50%), Dimensional Fund Advisors LP (3.21%), Krensavage Asset Management LLC (2.76%), Krensavage Asset Management LLC (2.75%) and Acadian Asset Management LLC (1.79%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Acadian Asset Management LLC, Great Point Partners LLC, Mackenzie Financial Corp, First Trust Advisors LP, First Manhattan Co., Barclays PLC and BlackRock Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., Candriam Luxembourg S.C.A., Two Sigma Investments LP, Krensavage Asset Management LLC, Krensavage Asset Management LLC, Millennium Management LLC, KBC Group NV and Dimensional Fund Advisors LP. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $99.64.

Enanta Pharmaceuticals has a market capitalization of $1.94 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

The official website for Enanta Pharmaceuticals is http://www.enanta.com.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]